Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Non-randomized Study of Neoadjuvant Low-dose Immunotherapy in Patients With Locally Advanced Colorectal Cancer With Microsatellite Instability (MSI)/Mismatch Repair Deficiency (dMMR)

NCT07523763 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.

NCT NCT07523763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Non-randomized Study of Neoadjuvant Low-dose Immunotherapy in Patients With Locally Advanced Colorectal Cancer With Microsatellite Instability (MSI)/Mismatch Repair Deficiency (dMMR)
Lead sponsor
Blokhin's Russian Cancer Research Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 22, 2024
Completion date
March 31, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), colorectal cancer (msi-h)